LANCL2

LanC-like protein 2 · Q9NS86 · LANCL2 on Sugi Atlas →

661 patent compounds predicted against LANCL2, 547 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Omilancor Omilancor (SCHEMBL17706588) 1.00 1/20
Omilancor Omilancor (SCHEMBL29349469) 1.00 1/20
SCHEMBL21043129 SCHEMBL21043129 0.93 1/20
SCHEMBL17705594 SCHEMBL17705594 0.88 1/20
SCHEMBL18805072 SCHEMBL18805072 0.88 1/20
SCHEMBL25877375 SCHEMBL25877375 0.86 1/20
SCHEMBL29466338 SCHEMBL29466338 0.86 1/20
SCHEMBL29063415 SCHEMBL29063415 0.84 1/20
SCHEMBL23561738 SCHEMBL23561738 0.83 1/20
SCHEMBL25877794 SCHEMBL25877794 0.82 1/20
SCHEMBL25882642 SCHEMBL25882642 0.81 1/20
SCHEMBL25310346 SCHEMBL25310346 0.81 1/20
SCHEMBL25311793 SCHEMBL25311793 0.80 1/20
SCHEMBL29466269 SCHEMBL29466269 0.80 1/20
SCHEMBL25311738 SCHEMBL25311738 0.80 1/20
SCHEMBL29063389 SCHEMBL29063389 0.80 1/20
SCHEMBL29466328 SCHEMBL29466328 0.80 1/20
SCHEMBL17705588 SCHEMBL17705588 0.79 1/20
SCHEMBL21705044 SCHEMBL21705044 0.79 1/20
SCHEMBL25313038 SCHEMBL25313038 0.79 1/20

Clinical trials — most relevant to LANCL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) PHASE2/PHASE3COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
LEAP2 Kinetics in Healthy Individuals EARLY_PHASE1COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
Common Genetic Variation and Type 2 Diabetes nanCOMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study nanCOMPLETED
Epidemiological and Genetic Studies of Body Mass Index nanCOMPLETED
Serum NGAL IN Patients With Multiple Myeloma nanUNKNOWN
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Action Medical Research nanCOMPLETED
Longitudinal Study of the Porphyrias nanRECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism nanACTIVE_NOT_RECRUITING
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia nanCOMPLETED
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis nanCOMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy. nanCOMPLETED
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With Classic Polycystic Ovary Syndrome (PCOS) nanNOT_YET_RECRUITING
Epidemiology of Gout in French Polynesia nanCOMPLETED
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects) nanUNKNOWN
The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity nanCOMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LANCL2 binder may also engage these)

ProteinNameSimilarity
Q9JJK2 1.000 Q9JJK2 →
Q9QX69 0.995 Q9QX69 →
F4IEM5 0.993 F4IEM5 →
F1MVX2 0.992 F1MVX2 →
Q90ZL2 0.990 Q90ZL2 →
O89112 0.990 O89112 →
Q9Y0Y7 0.990 Q9Y0Y7 →
LANCL1 Glutathione S-transferase LANCL1 0.988 landscape →
Q29HZ1 0.988 Q29HZ1 →
Q8VZQ6 0.987 Q8VZQ6 →
Q9FJN7 0.987 Q9FJN7 →
Q02293 0.980 Q02293 →
Q9NWZ5 0.980 Q9NWZ5 →
Q28DB0 0.980 Q28DB0 →
Q2KNB7 0.978 Q2KNB7 →
P56523 0.978 P56523 →
Q91YL3 0.978 Q91YL3 →
Q7Z7L7 0.978 Q7Z7L7 →
Q9VUL1 0.977 Q9VUL1 →
P49355 0.977 P49355 →
Q16GH0 0.977 Q16GH0 →
Q96BT7 0.976 Q96BT7 →
Q9NFT7 0.976 Q9NFT7 →
Q95K79 0.976 Q95K79 →
Q7ZW24 0.976 Q7ZW24 →
Q6P4W7 0.976 Q6P4W7 →
Q7QIL2 0.976 Q7QIL2 →
Q8K2I1 0.976 Q8K2I1 →
P49872 0.976 P49872 →
Q2KHV5 0.976 Q2KHV5 →